Dendrite to Provide Global Clinical Trial Support Services to One of the World’s Leading Pharmaceutical Companies
Dendrite International, Inc. announced it has been selected by another one of the world’s leading pharmaceutical companies to provide a broad range of clinical trial support services to enable the company to conduct global clinical trials more safely, expeditiously, and cost effectively.
Under a multi-year agreement with this new clinical services customer, Dendrite’s clinical support centers in the United States, United Kingdom, and Australia will provide around-the-clock e-Clinical support services for the company’s clinical trial sites utilizing Oracle® Clinical Remote Data Capture. This solution enables clinical trial data to be collected electronically at the source to help reduce delays and errors associated with paper-based processes.
Dendrite will provide 24×7, multilingual help desk support for clinical investigators, providing front-line support for hardware, communications, and application usage issues. Dendrite will also procure, image, test, ship, and support computer hardware and facilitate Internet connectivity.
“ In the pharmaceutical industry and at our company, electronic data capture is an increasingly critical component in managing global clinical data utilized in the development and life cycle management phases of the R&D process,” Dendrite’s client stated. “Electronic data capture enables us to fulfill our commitment to demonstrate reduced cycle time, productivity improvement, and significant cost savings.”
Added Cort Grey, Director of Sales and Marketing of Dendrite’s Clinical Development solutions, ”While the proper collection and verification of medical data is one of the most important activities during clinical trials, the traditional paper-based approach toward data capture has often compromised the process. This key client has made a corporate commitment to accelerate its utilization of electronic data capture technology, and while the move to a high- tech solution is significant, the commitment to maintaining investigator efficiency and satisfaction is even more so. We are pleased that Dendrite can play a global support role in helping this company enhance its clinical trial processes around the world.”
About Dendrite
Dendrite develops and delivers solutions that increase the productivity of sales, marketing, and clinical processes for pharmaceutical and other life science clients . For more information, visit www.dendrite.com .
Media Inquiries
Erik Kopp
908-541-5850
erik.kopp@dendrite.com
Note: Dendrite is a registered trademark of Dendrite International, Inc.
This document contains forward-looking statements that may be identified by such forward-looking terminology as “expect,” “believe,” “anticipate,” “will,” “intend,” “plan,” “target,” “outlook,” “guidance,” and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues and variations in customers’ budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions, including the success of the acquisition of Synavant and other acquisitions and the risks associated with the integration of acquisitions; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company’s 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.
